Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from Bristol-Meyers…
Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said it would not seek US Food and Drug Administration approval for its…
Paul Ausick Increasing numbers of mutual funds have performances tied to huge investments in Apple (NASDAQ: AAPL). (Reuters) Tim Cook, Apple’s CEO, is in China to address production labor problems. (Reuters) The European Union…
We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva…
Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company had sought…
Paul Ausick Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a trial in…
Paul Ausick US equity markets opened lower this morning, but after the first hour or so of trading, the three major indexes moved to positive territory where they remained for the rest of the…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning. AON Corporation (NYSE: AON) Cut to Neutral at Citigroup.…
Today is Facebook Day. It will be remembered that way as long as there are IPOs. The Facebook public offering has every aspect of what makes IPOs the focus of so much interest.…
Drug maker AstraZeneca PLC (NYSE: AZN) has issued a press release re-confirming the company’s December forecast following a load of bad data sent to analysts: During a routine consensus collection process, confidential…
Paul Ausick Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed earlier forecasts. Looking…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning. AstraZeneca PLC (NYSE: AZN) Cut to Underweight at JPMorgan. BlackRock,…
Pharmaceutical company AstraZeneca plc (NYSE: AZN) is looking for another big winner to replace its Nexium heartburn drug and its Seroquel schizophrenia treatment. Unfortunately two drugs the company had in trials both…
Paul Ausick Layoffs were part of the business news yesterday. Enough people lost jobs in a series of three “downsizings” to reminds those who believe unemployment continues to fall that the economy still struggles.…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie…
